Checkpoint Therapeutics Inc reports results for the quarter ended in March - Earnings Summary

Checkpoint Therapeutics

15/05/2023 23:41

* Checkpoint Therapeutics Inc  CKPT.OQ  reported a quarterly
adjusted loss of 89 cents​​ per share for the quarter ended in
March. The mean expectation of five analysts for the quarter was
for a loss of $1.07 per share.
    * Revenue fell 32.7% to $35.00 thousand from a year ago;
analysts
expected $16.67 thousand. 
    * Checkpoint Therapeutics Inc's reported EPS for the quarter
was a
loss of 89 cents​.
    * The mean earnings estimate of analysts had fallen by
about 0.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Checkpoint Therapeutics Inc shares had risen by 16.4% this
quarter and lost 48.7% so far this year.
    * The company reported a quarterly loss of $10.47 million.
    * Wall Street's median 12-month price target for Checkpoint
Therapeutics Inc is $34.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 10:41 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -1.07          -0.89          Beat
 Dec. 31 2022      -1.31          -2.29          Missed
 Sep. 30 2022      -1.47          -1.20          Beat
 Jun. 30 2022      -1.72          -1.60          Beat